ACM
QNCX icon

ADAR1 Capital Management’s Quince Therapeutics QNCX Stock Holding History

ADAR1 Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250
Closed -$5.07K – 328
2026
Q1 		$5.07K Sell
250
-150
-38% -$30.1K ﹤0.01% 309
2025
Q4 		$268K Buy
+400
New +$201K 0.02% 214

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ADAR1 Capital Management's QNCX Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 251 shares — an estimated $5.08K sold.

ADAR1 Capital Management first reported a position in QNCX in Q1 2024 and held it in 9 quarters. The position peaked at $1.26M in Q3 2025. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 251 Quince Therapeutics shares in Q2 2026, an estimated $5.08K.
  • ADAR1 Capital Management first reported a position in Quince Therapeutics in Q1 2024 and held it in 9 quarters.
  • ADAR1 Capital Management's Quince Therapeutics position peaked at $1.26M in Q3 2025.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.